Cargando…

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515451/ https://www.ncbi.nlm.nih.gov/pubmed/34645684 http://dx.doi.org/10.1136/jitc-2021-003521corr1

Ejemplares similares

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

Correction: Interactions of the chemokines CXCL11 and CXCL12 in human tumor cells
por: Koch, Christian, et al.
Publicado: (2023)

Correction to: Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
por: Hao, Zhaonian, et al.
Publicado: (2022)

Correction: Expression of IL-27 by Tumor Cells in Invasive Cutaneous and Metastatic Melanomas
por: Gonin, Julie, et al.
Publicado: (2013)

Correction: FRIZZLED7 Is Required for Tumor Inititation and Metastatic Growth of Melanoma Cells
por: Tiwary, Shweta, et al.
Publicado: (2017)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

Correction: Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
Publicado: (2022)

Correction: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Correction to: Daphnane diterpenes inhibit the metastatic potential of B16F10 murine melanoma cells in vitro and in vivo
por: Villareal, Myra O., et al.
Publicado: (2018)

Correction: BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells
por: Romano, Erminia, et al.
Publicado: (2018)

Correction: Heme-Mediated Induction of CXCL10 and Depletion of CD34+ Progenitor Cells Is Toll-Like Receptor 4 Dependent
por: Dickinson-Copeland, Carmen M., et al.
Publicado: (2016)

Correction: Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
Publicado: (2023)

Correction: Foam cells promote atherosclerosis progression by releasing CXCL12
Publicado: (2022)

Correction: CXCL10 Controls Inflammatory Pain via Opioid Peptide-Containing Macrophages in Electroacupuncture
Publicado: (2014)

Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
Publicado: (2020)

Correction to: CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS
por: Blot, Mathieu, et al.
Publicado: (2021)

Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2020)

Correction: C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
Publicado: (2020)

Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response
por: Antoranz, Asier, et al.
Publicado: (2022)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2015)

Correction: T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
Publicado: (2021)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

Correction to: Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy
por: Xu, Longwen, et al.
Publicado: (2019)

Correction: Up-Regulation of Hepatoma-Derived Growth Factor Facilities Tumor Progression in Malignant Melanoma
por: Tsai, Han-En, et al.
Publicado: (2013)

Correction to T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy
Publicado: (2023)

Correction to: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2022)

Correction: Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy
por: Lecavalier-Barsoum, Magali, et al.
Publicado: (2019)

Correction: Metastatic breast cancers have reduced immune cell recruitment but harbour increased macrophages relative to their matched primary tumors
Publicado: (2020)

Correction to: CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling
por: Xiu, Weigang, et al.
Publicado: (2021)

Correction: Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
Publicado: (2015)

Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy: Melanoma brain metastases prognostic score
por: Schaule, Jana, et al.
Publicado: (2020)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Correction: Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
Publicado: (2020)

Correction to: Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
por: Furune, Satoshi, et al.
Publicado: (2021)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Correction: Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses
por: Zheng, Huaguo, et al.
Publicado: (2019)

Correction: EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer
por: Schneck, Helen, et al.
Publicado: (2016)

Correction: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
por: Lu, Jun, et al.
Publicado: (2022)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Correction: CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cnhlohni82oahae7kqej738l7e